180 Life Sciences
Biotechnology, Blockchain, Cryptocurrency · 4 employees
180 Life Sciences Corp. is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
Funding history
- Series seed — $2.9M — Jan 2025
- Funding Round — $15.0M — Sep 2021
- Funding Round — $11.7M — Feb 2021
Recent signals
- Mar 28, 2026: Acquired Forum Markets acquires loan portfolio from Zippy Loans
- Mar 03, 2026: Forum Markets Appoints Robert Spake as General Counsel
- Oct 22, 2025: SEC 8-K (1.01): On October 22, 2025, ETHZilla Corporation entered into a Purchase and Subscription Agreement with Satschel, Inc., a Delaware corporation. Under this agreement, Satschel sold 15% of its fully-diluted capitalization represented by its Class A Common Stock to ETHZilla in exchange for $5 million in cash and 556,174 shares of ETHZilla's common stock. This transaction enhances ETHZilla's position in the digital trading space by obtaining equity in a regulated broker-dealer and operates a Digital Alternative Trading System, which could lead to strategic synergies for both companies. The agreement illustrates ETHZilla’s continued efforts to expand its market reach and operational capabilities through significant equity investments.
- Jan 10, 2025: Raised $2.9M in Series seed
- Sep 12, 2024: 180 Life Sciences Appoints Omar Jimenez as Chief Financial Officer
- Sep 01, 2021: Raised $15.0M
- Feb 26, 2021: Raised $11.7M
See plans & pricing → Track 180 Life Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.